KEY DETAILS
Lilly is moving into new therapeutic areas beyond obesity, signaling that its future plans reach past weight loss drugs alone.
Lilly's push to expand past its top growth drivers suggests the company wants steady momentum even as obesity drug competition grows.
People taking GLP-1 medications may face stigma from friends and family, according to a new study on social attitudes toward these drugs.
In the REIMAGINE 5 trial, CagriSema produced greater weight loss than a 5 mg dose of tirzepatide, giving patients another comparison point.
New research shows GLP-1s and SGLT-2 drugs slow kidney decline mainly in people who already have albuminuria, not in everyone who takes them.
Eli Lilly signaled today that its future extends well past obesity, with new therapeutic areas now part of the company's stated plans. That expansion matters because it shows Lilly wants growth that does not depend entirely on weight loss drugs, even as competition in that market intensifies. The same day brought a new head-to-head comparison between CagriSema and a 5 mg dose of tirzepatide, along with fresh research on social stigma and on which patients actually see a kidney benefit from these drugs.
Lilly's announcement centers on expanding its drug development beyond obesity and diabetes, the two areas that have driven much of its recent growth. The company is signaling that it sees its future built on a wider set of therapeutic areas rather than a narrow bet on weight loss alone. For patients and investors watching the GLP-1 market, this suggests Lilly is not treating its obesity franchise as the endpoint of its ambitions but as one part of a larger plan.
That broader ambition lines up with a separate assessment of Lilly's strategy, which points out that the company is expanding past its biggest current growth drivers, including its GLP-1 franchise, in order to sustain momentum over time. The reasoning is straightforward: obesity drug competition is intensifying, with more companies entering the market and existing players refining their own offerings. If Lilly can build strength in other therapeutic areas, it reduces how much its overall performance depends on any single drug class holding its lead. That kind of diversification is a common move for a company facing new competitors, and it may reassure investors watching how crowded the obesity drug market has become.
Away from the boardroom, a new study looks at how GLP-1 users are treated by the people closest to them, and it found that stigma from friends and family is common. Patients taking these medications for weight loss or diabetes reported facing judgment or skepticism from the very people they might expect support from. This matters because it can affect whether someone feels comfortable starting or continuing treatment, regardless of how well the drug itself works. The finding is a reminder that the social response to GLP-1 medications has not caught up with how common they have become.
On the clinical side, the REIMAGINE 5 trial gave patients and doctors another data point for comparing weight loss drugs, showing that CagriSema produced greater weight loss than a 5 mg dose of tirzepatide. This comparison is useful because it clarifies how CagriSema performs against a specific, moderate dose of Lilly's drug, rather than against a placebo alone. Patients or clinicians deciding between these options now have more direct evidence to weigh, even though a 5 mg dose is not the highest one tirzepatide is approved for. It is a narrow but concrete comparison, and it adds to the broader picture of how the newer generation of obesity drugs stack up against each other.
A similar note of nuance appears in new research on GLP-1s and SGLT-2 drugs and their effect on kidney function. The study found that these medications slow kidney decline mainly in people who already have albuminuria, a marker of kidney damage, rather than producing that benefit across everyone who takes them. That distinction matters for how doctors think about prescribing these drugs for kidney protection specifically, since the benefit does not appear to be universal. It also suggests that patients without albuminuria should not necessarily expect the same kidney related outcomes, even if they see benefits in weight or blood sugar control.
None of this changes what to do this week, but it does add useful context. Lilly's broader ambitions and the growing precision of GLP-1 research, from dose comparisons to kidney outcomes, suggest this is a fast moving area of medicine, and the specifics matter more than the headlines. If you are on one of these drugs, it may be worth asking your doctor how new findings like the albuminuria research apply to your own labs. And if you have felt judged for taking a GLP-1 medication, it helps to remember that other people's reactions say nothing about whether the medication is working for you.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.